ClinicalTrials.gg
CompletedNCT02799381DYSCOVERUpdated Aug 18, 2020Results posted

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

A Phase 3 interventional study of Optimized antiparkinsonian treatment and Levodopa-Carbidopa Intestinal Gel (LCIG) in Parkinson's Disease (PD), sponsored by AbbVie. Completed at 28 sites in 7 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2020-08-18.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Parkinson Disease by AbbVie — 6 open to participants now, 9 under way, none of them phase 3. Parkinson Disease · AbbVie.

Enrollment
13th of 25
63 · median 63
Started
2017
with 2 others
Phase 3
16 of 44
none open now
Registered
16th of 44
by date

Among the 44 studies in Parkinson Disease by AbbVie, this one is the 13th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2017, is one of 16 in phase 3, and was the 16th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 44 studies in Parkinson Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Parkinson Disease by AbbVie, or all of them as a file.
02

Study summary

The primary objective of this study was to examine the effect of levodopa-carbidopa intestinal gel (LCIG) compared with optimized medical treatment (OMT) on dyskinesia in participants with advanced Parkinson's disease (PD).

Read the detailed description

This was a Phase 3b, open-label, randomized, multicenter, 12-week study. The study consisted of 3 sequential periods: Screening, Treatment, and Follow-Up. The OMT group had the same schedule of visits/procedures throughout the study as the LCIG treatment group, except for visits related to nasojejunal (NJ)/percutaneous endoscopic gastrostomy (PEG) procedures, titration of LCIG, and follow-up period.

03

Conditions studied

  • Parkinson's Disease (PD)

Browse trials for

Keywords

  • Carbidopa
  • Levodopa
  • Efficacy
  • Levodopa-carbidopa intestinal gel
  • Advanced Parkinson's Disease
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a diagnosis of idiopathic Parkinson's disease (PD) according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria
  • Participants with advanced levodopa-responsive PD and persistent motor fluctuations who have not been controlled with optimized medical treatment (OMT: the maximum therapeutic effect obtained with pharmacological antiparkinsonian therapies when no further improvement is expected with regard to any additional manipulations of levodopa and/or other antiparkinsonian medication based on the Investigator's clinical judgment)
  • Unified Dyskinesia Rating Scale (UDysRs) Total score ≥ 30 at Visit 3

Exclusion criteria

Exclusion Criteria:

  • Participant(s) treated with levodopa-carbidopa intestinal gel (LCIG) previously
  • Participant's PD diagnosis is unclear or there is a suspicion that the subject has a parkinsonian syndrome such as secondary parkinsonism (e.g. caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), parkinson-plus syndrome (e.g. Multiple System Atrophy, Progressive supranuclear Palsy, Diffuse Lewy Body disease) or other neurodegenerative disease that might mimic the symptoms of PD
  • Participant(s) has undergone neurosurgery for the treatment of Parkinson's disease.
  • Participant(s) has to levodopa (e.g. narrow angle glaucoma, malignant melanoma)
  • Participant(s) experiencing sleep attacks or clinically significant impulsive behavior (e.g. pathological gambling, hypersexuality) at any point during the three months prior to the Screening evaluation as judged by the Principal Investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Active comparator
    Optimized Medical Treatment (OMT)

    Participants randomized to OMT continued their current anti Parkinson's disease (anti-PD) medication regimen for the duration of the study. All anti-PD medications and medications to treat dyskinesia must have remained stable for the duration of the study unless adjustments were medically indicated. The Investigator provided the prescription for continued OMT.

    Drug: Optimized antiparkinsonian treatment

  • Experimental
    Levodopa-Carbidopa Intestinal Gel (LCIG)

    The total daily dose of infusion LCIG was composed of three components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. A temporary nasojejunal (NJ) tube may have been used initially with the infusion pump to determine a participant's response to this method of treatment and to optimize the dose of LCIG before treatment with a permanent percutaneous endoscopic gastrostomy - with jejunal extension (PEG-J) tube was started. Following optional NJ and/or PEG-J placement and, at the investigator's discretion, the participant may have begun initiation and titration of LCIG infusion on Day 1 once tube placement was confirmed. The dose of LCIG was adjusted to obtain the optimal clinical response. The rate of LCIG infusion is typically within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances and runs over a period of 16 consecutive hours each day.

    Drug: Levodopa-Carbidopa Intestinal Gel (LCIG) · Device: CADD-Legacy ambulatory infusion pump · Device: Percutaneous endoscopic gastrostomy tube · Device: Jejunal extension tube

Interventions

  • DrugOptimized antiparkinsonian treatment

    Dose levels of prescribed antiparkinsonian medications were individually optimized to their maximum therapeutic effect.

  • DrugLevodopa-Carbidopa Intestinal Gel (LCIG)

    Dose levels were individually optimized.

    Also known as: ABT-SLV187, DUOPA (carbidopa and levodopa Enteral Suspension), DUODOPA

  • DeviceCADD-Legacy ambulatory infusion pump

    (manufactured by Smiths Medical)

  • DevicePercutaneous endoscopic gastrostomy tube

    (PEG tube)

  • DeviceJejunal extension tube

    (J-tube)

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline to Week 12 in Unified Dyskinesia Rating Scale (UDysRS) Total Score

    The Unified Dyskinesia Rating Scale (UDysRS) is a tool used to assess dyskinesia in Parkinson's disease (PD) and contains both self-evaluation questions and items that are assessed directly by the physician to objectively rate the abnormal movements associated with PD. Part 1 contains 11 questions about the ON time dyskinesia and the impact of ON-dyskinesia on experiences of daily living. Part 2 contains 4 questions about OFF-dystonia rating. Part 3 contains 7 questions about objective evaluation of dyskinesia impairment and Part 4 contains 4 questions regarding dyskinesia disability. Each question is scored with respect to severity, which is rated on a scale where 0 = normal, 1 = slight, 2 = mild, 3= moderate and 4 = severe. The UDysRS total score is obtained by summing the item scores, ranging from 0 to 104. Higher scores are associated with more disability. Negative changes from baseline indicate improvement.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Mean Change From Baseline to Week 12 in ON Time Without Troublesome Dyskinesia

    The Parkinson's Disease (PD) Symptom Diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected study visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e., 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. ON time is when PD symptoms are well controlled by the drug, and OFF time is when PD symptoms are not adequately controlled by the drug. Positive change from baseline for ON time without troublesome dyskinesia indicates improvement.

    Time frame: Baseline, Week 12

  2. Mean Change From Baseline to Week 12 in Parkinson's Disease Questionnaire-8 (PDQ-8) Summary Index

    The Parkinson's Disease Questionnaire-8 (PDQ-8) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with PD, and which may not be included in general health status questionnaires. The PDQ-8 is a self-administered questionnaire. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Higher scores are consistently associated with the more severe symptoms of the disease such as tremors and stiffness. The results are presented as a summary index. The PDQ-8 summary index ranges from 0 to 100, where lower scores indicate a better perceived health status. Negative changes from baseline indicate improvement.

    Time frame: Baseline, Week 12

  3. Mean Clinical Global Impression of Change (CGI-C) Score at Week 12

    The Clinical Global Impression of Change (CGI-C) score is a clinician's rating scale for assessing Global Improvement of Change. The CGI-C rates improvement by 7 categories: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6), very much worse (7). The CGI-C score ranges from 1 to 7, with lower scores indicating improvement.

    Time frame: Baseline, Week 12

  4. Mean Change From Baseline to Week 12 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score (Activities of Daily Living)

    The Unified Parkinson's Disease Rating Scale (UPDRS) is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions related to Activities of Daily Living, and ranges from 0-52. Higher scores are associated with more disability. Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 12

  5. Mean Change From Baseline to Week 12 in OFF Time

    The Parkinson's Disease (PD) Symptom Diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected study visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e., 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. ON time is when PD symptoms are well controlled by the drug, and OFF time is when PD symptoms are not adequately controlled by the drug. Negative change from baseline for OFF time indicates improvement.

    Time frame: Baseline, Week 12

  6. Mean Change From Baseline to Week 12 in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score (Motor Examination)

    The Unified Parkinson's Disease Rating Scale (UPDRS) is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers related to Motor Examination, and ranges from 0-108. Higher scores are associated with more disability. Negative values indicate improvement from baseline.

    Time frame: Baseline, Week 12

07

Results

Posted Aug 18, 2020

Participant flow

Participant flow — Overall Study
MilestoneOptimized Medical Treatment (OMT)Levodopa-Carbidopa Intestinal Gel (LCIG)
Started3328
Completed2925
Not completed43
Withdrew: Withdrew consent32
Withdrew: Adverse event01
Withdrew: Participant did not take any study drug10

Outcome measures

PrimaryMean Change From Baseline to Week 12 in Unified Dyskinesia Rating Scale (UDysRS) Total Score

The Unified Dyskinesia Rating Scale (UDysRS) is a tool used to assess dyskinesia in Parkinson's disease (PD) and contains both self-evaluation questions and items that are assessed directly by the physician to objectively rate the abnormal movements associated with PD. Part 1 contains 11 questions about the ON time dyskinesia and the impact of ON-dyskinesia on experiences of daily living. Part 2 contains 4 questions about OFF-dystonia rating. Part 3 contains 7 questions about objective evaluation of dyskinesia impairment and Part 4 contains 4 questions regarding dyskinesia disability. Each question is scored with respect to severity, which is rated on a scale where 0 = normal, 1 = slight, 2 = mild, 3= moderate and 4 = severe. The UDysRS total score is obtained by summing the item scores, ranging from 0 to 104. Higher scores are associated with more disability. Negative changes from baseline indicate improvement.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Week 12 in Unified Dyskinesia Rating Scale (UDysRS) Total Score
units on a scaleOptimized Medical Treatment (OMT)Levodopa-Carbidopa Intestinal Gel (LCIG)
Mean Change From Baseline to Week 12 in Unified Dyskinesia Rating Scale (UDysRS) Total Score-2.33 ± 2.56-17.37 ± 2.79
Statistical analysis
  • Optimized Medical Treatment (OMT) vs Levodopa-Carbidopa Intestinal Gel (LCIG) · Mixed-effects model repeated measures · p = <0.0001 (Two-sided p-value) · Ls mean difference: -15.05 · 95% CI -21.47 to -8.63Levodopa-Carbidopa Intestinal Gel (LCIG) - Optimized Medical Treatment (OMT) at Week 12
SecondaryMean Change From Baseline to Week 12 in ON Time Without Troublesome Dyskinesia

The Parkinson's Disease (PD) Symptom Diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected study visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e., 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. ON time is when PD symptoms are well controlled by the drug, and OFF time is when PD symptoms are not adequately controlled by the drug. Positive change from baseline for ON time without troublesome dyskinesia indicates improvement.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · hours
Mean Change From Baseline to Week 12 in ON Time Without Troublesome Dyskinesia
hoursOptimized Medical Treatment (OMT)Levodopa-Carbidopa Intestinal Gel (LCIG)
Mean Change From Baseline to Week 12 in ON Time Without Troublesome Dyskinesia-0.12 ± 0.633.15 ± 0.69
Statistical analysis
  • Optimized Medical Treatment (OMT) vs Levodopa-Carbidopa Intestinal Gel (LCIG) · Mixed-effects model repeated measures · p = <0.0001 (Two-sided p-value) · Ls mean difference: 3.27 · 95% CI 1.71 to 4.83Levodopa-Carbidopa Intestinal Gel (LCIG) - Optimized Medical Treatment (OMT) at Week 12
SecondaryMean Change From Baseline to Week 12 in Parkinson's Disease Questionnaire-8 (PDQ-8) Summary Index

The Parkinson's Disease Questionnaire-8 (PDQ-8) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with PD, and which may not be included in general health status questionnaires. The PDQ-8 is a self-administered questionnaire. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Higher scores are consistently associated with the more severe symptoms of the disease such as tremors and stiffness. The results are presented as a summary index. The PDQ-8 summary index ranges from 0 to 100, where lower scores indicate a better perceived health status. Negative changes from baseline indicate improvement.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Week 12 in Parkinson's Disease Questionnaire-8 (PDQ-8) Summary Index
units on a scaleOptimized Medical Treatment (OMT)Levodopa-Carbidopa Intestinal Gel (LCIG)
Mean Change From Baseline to Week 12 in Parkinson's Disease Questionnaire-8 (PDQ-8) Summary Index-4.95 ± 3.11-21.62 ± 3.47
Statistical analysis
  • Optimized Medical Treatment (OMT) vs Levodopa-Carbidopa Intestinal Gel (LCIG) · Mixed-effects model repeated measures · p = <0.0001 (Two-sided p-value) · Ls mean difference: -16.66 · 95% CI -24.48 to -8.85Levodopa-Carbidopa Intestinal Gel (LCIG) - Optimized Medical Treatment (OMT) at Week 12
SecondaryMean Clinical Global Impression of Change (CGI-C) Score at Week 12

The Clinical Global Impression of Change (CGI-C) score is a clinician's rating scale for assessing Global Improvement of Change. The CGI-C rates improvement by 7 categories: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6), very much worse (7). The CGI-C score ranges from 1 to 7, with lower scores indicating improvement.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Mean Clinical Global Impression of Change (CGI-C) Score at Week 12
units on a scaleOptimized Medical Treatment (OMT)Levodopa-Carbidopa Intestinal Gel (LCIG)
Mean Clinical Global Impression of Change (CGI-C) Score at Week 124.58 ± 0.252.48 ± 0.28
Statistical analysis
  • Optimized Medical Treatment (OMT) vs Levodopa-Carbidopa Intestinal Gel (LCIG) · Mixed-effects model repeated measures · p = <0.0001 (Two-sided p-value) · Ls mean difference: -2.11 · 95% CI -2.78 to -1.44Levodopa-Carbidopa Intestinal Gel (LCIG) - Optimized Medical Treatment (OMT) at Week 12
SecondaryMean Change From Baseline to Week 12 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score (Activities of Daily Living)

The Unified Parkinson's Disease Rating Scale (UPDRS) is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions related to Activities of Daily Living, and ranges from 0-52. Higher scores are associated with more disability. Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Week 12 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score (Activities of Daily Living)
units on a scaleOptimized Medical Treatment (OMT)Levodopa-Carbidopa Intestinal Gel (LCIG)
Mean Change From Baseline to Week 12 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score (Activities of Daily Living)0.21 ± 1.16-5.33 ± 1.28
Statistical analysis
  • Optimized Medical Treatment (OMT) vs Levodopa-Carbidopa Intestinal Gel (LCIG) · Mixed-effects model repeated measures · p = =0.0006 (Two-sided p-value) · Ls mean difference: -5.54 · 95% CI -8.59 to -2.49Levodopa-Carbidopa Intestinal Gel (LCIG) - Optimized Medical Treatment (OMT) at Week 12
SecondaryMean Change From Baseline to Week 12 in OFF Time

The Parkinson's Disease (PD) Symptom Diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected study visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e., 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. ON time is when PD symptoms are well controlled by the drug, and OFF time is when PD symptoms are not adequately controlled by the drug. Negative change from baseline for OFF time indicates improvement.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · hours
Mean Change From Baseline to Week 12 in OFF Time
hoursOptimized Medical Treatment (OMT)Levodopa-Carbidopa Intestinal Gel (LCIG)
Mean Change From Baseline to Week 12 in OFF Time0.18 ± 0.49-2.17 ± 0.53
Statistical analysis
  • Optimized Medical Treatment (OMT) vs Levodopa-Carbidopa Intestinal Gel (LCIG) · Mixed-effects model repeated measures · p = =0.0002 (Two-sided p-value) · Ls mean difference: -2.35 · 95% CI -3.51 to -1.19Levodopa-Carbidopa Intestinal Gel (LCIG) - Optimized Medical Treatment (OMT) at Week 12
SecondaryMean Change From Baseline to Week 12 in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score (Motor Examination)

The Unified Parkinson's Disease Rating Scale (UPDRS) is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers related to Motor Examination, and ranges from 0-108. Higher scores are associated with more disability. Negative values indicate improvement from baseline.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Week 12 in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score (Motor Examination)
units on a scaleOptimized Medical Treatment (OMT)Levodopa-Carbidopa Intestinal Gel (LCIG)
Mean Change From Baseline to Week 12 in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score (Motor Examination)-0.87 ± 1.89-4.93 ± 2.08
Statistical analysis
  • Optimized Medical Treatment (OMT) vs Levodopa-Carbidopa Intestinal Gel (LCIG) · Mixed-effects model repeated measures · p = =0.0762 (Two-sided p-value) · Ls mean difference: -4.05 · 95% CI -8.55 to 0.44Levodopa-Carbidopa Intestinal Gel (LCIG) - Optimized Medical Treatment (OMT) at Week 12

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) collection: OMT (starting after the day of randomization until 30 days after the last visit, up to 18 weeks); LCIG group with study tube removal after the last study drug infusion (from the time of tube placement up to 30 days following tube removal, up to 16 weeks); other LCIG participants (starting with tube placement and up to 30 days following the last study visit, up to 16 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levodopa-Carbidopa Intestinal Gel (LCIG)0/28 (0%)2/28 (7.1%)15/28 (53.6%)
Optimized Medical Treatment (OMT)0/33 (0%)0/33 (0%)4/33 (12.1%)
Most frequent serious events
Most frequent serious events
EventLevodopa-Carbidopa Intestinal Gel (LCIG)Optimized Medical Treatment (OMT)
PNEUMOPERITONEUMGastrointestinal disorders1/280/33
CYSTITISInfections and infestations1/280/33
SYNCOPENervous system disorders1/280/33
HYPERTENSIONVascular disorders1/280/33
Most frequent other events
Most frequent other events
EventLevodopa-Carbidopa Intestinal Gel (LCIG)Optimized Medical Treatment (OMT)
FALLInjury, poisoning and procedural complications6/282/33
PROCEDURAL PAINInjury, poisoning and procedural complications3/280/33
ABDOMINAL PAINGastrointestinal disorders2/280/33
DIARRHOEAGastrointestinal disorders2/280/33
DRUG WITHDRAWAL SYNDROMEGeneral disorders2/280/33
URINARY TRACT INFECTIONInfections and infestations2/280/33
MUSCLE SPASMSMusculoskeletal and connective tissue disorders2/280/33
ANXIETYPsychiatric disorders2/280/33
DEPRESSIONPsychiatric disorders2/281/33
PARKINSON'S DISEASENervous system disorders1/282/33

Baseline characteristics

Safety Data Set: all participants randomized to OMT and all participants randomized to LCIG treatment who had a study tube (NJ or PEG-J) placement procedure. Two participants randomized to the LCIG arm did not have device placement for LCIG infusion and were not included in the safety data set.

Age, Continuous
Age, Continuous(years)Optimized Medical Treatment (OMT)Levodopa-Carbidopa Intestinal Gel (LCIG)Total
Mean68.7 ± 7.2069.3 ± 6.9969.0 ± 7.05
Sex: Female, Male
Sex: Female, Male(Participants)Optimized Medical Treatment (OMT)Levodopa-Carbidopa Intestinal Gel (LCIG)Total
Female161632
Male171229
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Optimized Medical Treatment (OMT)Levodopa-Carbidopa Intestinal Gel (LCIG)Total
White332861
Black or African American000
Asian000
American Indian or Alaska Native000
Native Hawaiian or other Pacific Islander000
Missing000
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Optimized Medical Treatment (OMT)Levodopa-Carbidopa Intestinal Gel (LCIG)Total
Mean25.2 ± 4.4224.5 ± 4.2424.9 ± 4.32
Parkinson's disease duration (years)
Parkinson's disease duration (years)(Participants)Optimized Medical Treatment (OMT)Levodopa-Carbidopa Intestinal Gel (LCIG)Total
< 10 years14721
≥ 10 years192039
Missing011
08

Study locations

28 sites
  • Parkinson's Disease Treatment Center of Southwest Florida /ID# 150095
    Port Charlotte, Florida 33980, United States
  • Central Texas Neurology Consul /ID# 150088
    Round Rock, Texas 78681, United States
  • Helsinki Univ Central Hospital /ID# 151214
    Helsinki, 00290, Finland
  • Oulun yliopistollinen sairaala /ID# 150947
    Oulu, 90220, Finland
  • Mediterraneo Hospital /ID# 150955
    Glyfada, 16675, Greece
  • University General Hospital of Heraklion "PA.G.N.I" /ID# 150956
    Heraklion, 71110, Greece
  • University Hospital of Ioannin /ID# 150954
    Ioannina, 45500, Greece
  • Pecsi Tudomanyegyetem Klinikai Kozpont I. sz. Belgyogyaszati Klinika /ID# 170116
    Pécs, Pecs 7624, Hungary
  • Semmelweis Egyetem /ID# 170117
    Budapest, 1085, Hungary
  • Szegedi Tudomanyegyetem /ID# 170115
    Szeged, 6720, Hungary
  • Policlinico Universitario Campus Bio-Medico /ID# 150846
    Rome, Lazio 00128, Italy
  • A.O. Univ. Ospedali Riuniti /ID# 150853
    Ancona, Marche 60126, Italy
  • Azienda USL Toscana Centro /ID# 150770
    Florence, 50012, Italy
  • Seconda Universita' di Napoli /ID# 150851
    Naples, 80138, Italy
  • Policlinico Tor Vergata /ID# 151167
    Rome, 00133, Italy
  • Univerzitna nemocnica L. Pasteura /ID# 150146
    Košice - Západ, Kosicky Kraj 041 66, Slovakia
  • Univerzitna nemocnica Martin /ID# 150145
    Martin, Zilinsky Kraj 036 01, Slovakia
  • Univerzitna Nemocnica Bratislava /ID# 150144
    Bratislava, 821 01, Slovakia
  • Univerzitna Nemocnica Bratislava /ID# 150171
    Bratislava, 821 01, Slovakia
  • Hospital Regional Universitari /ID# 171485
    Málaga, Malaga 29010, Spain
  • Hospital Universitario Cruces /ID# 203807
    Barakaldo, 48903, Spain
  • Hospital General Univ de Elche /ID# 150154
    Elche, 03202, Spain
  • Hospital Univ de la Princesa /ID# 150157
    Madrid, 28006, Spain
  • Hospital General Universitario Gregorio Maranon /ID# 150155
    Madrid, 28007, Spain
  • Hospital Univ Ramon y Cajal /ID# 150152
    Madrid, 28034, Spain
  • Hospital Universitario Infanta /ID# 159696
    Madrid, 28702, Spain
  • Hospital Universitario Virgen Macarena /ID# 158861
    Sevilla, 41009, Spain
  • Hospital Virgen de la Salud /ID# 166297
    Toledo, 45005, Spain
09

References and documents

Publications

  • Freire-Alvarez E, Kurca E, Lopez Manzanares L, Pekkonen E, Spanaki C, Vanni P, Liu Y, Sanchez-Solino O, Barbato LM. Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial. Mov Disord. 2021 Nov;36(11):2615-2623. doi: 10.1002/mds.28703. Epub 2021 Jul 8. PubMed 34236101 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Sep 2019, 31 months.

Results were first posted in Aug 2020, 10 months after primary completion.

Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 31 months is close to that.

Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2016
First posted
Jun 14, 2016
StartActual
Feb 9, 2017
Primary completionActual
Sep 19, 2019
CompletionActual
Sep 19, 2019
Results first posted
Aug 18, 2020
Last update
Aug 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02799381
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 14, 2016
Start date
Feb 9, 2017
Primary completion
Sep 19, 2019
Completion
Sep 19, 2019
Results posted
Aug 18, 2020
Last update
Aug 18, 2020

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion